Q2 2026 13F · SEC CIK 1622627

Rosalind Advisors, Inc.

Investment managerFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $266.2M
Reported positions: 29
Top holdings a year, 3 yrs: +18.5%
Average holding period: 1.8 yrs

Rosalind Advisors, Inc. is an investment manager that reported 29 positions worth $266.2M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Delcath Sys Inc (DCTH, 15.6%), Fennec Pharmaceuticals Inc (FENC, 12.9%), Xeris Biopharma Holdings Inc (XERS, 8.7%). A portfolio copying its top holdings returned 18.5% a year over the last 3 years, against 16.5% for the S&P 500.

Rosalind Advisors, Inc. holdings all 29 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Rosalind Advisors, Inc. 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
DCTHDelcath Sys Inc	15.6%	12.5%	3,300,389	+0.0%	$41.6M
FENCFennec Pharmaceuticals Inc	12.9%	7.3%	3,188,001	+9.6%	$34.3M
XERSXeris Biopharma Holdings Inc	8.7%	7.7%	2,908,981	-10.0%	$23.0M
SVRASavara Inc	7.4%	7.2%	3,178,121	-0.8%	$19.6M
VSTMVerastem Inc	5.7%	4.6%	3,986,509	+86.4%	$15.2M
XFORX4 Pharmaceuticals Inc	5.6%	5.4%	3,214,766	+0.0%	$15.0M
EYPTEyepoint Pharmaceuticals Inc	5.3%	5.5%	988,230	-4.7%	$14.1M
23256X407Cybin Inc	4.9%	3.0%	1,956,814	+27.7%	$12.9M
VORVor Biopharma Inc	4.5%	5.1%	648,600	-7.3%	$11.9M
PCVXVaxcyte Inc	4.4%	6.9%	200,000	-31.0%	$11.6M
MDWDMediwound Ltd	4.1%	4.9%	749,054	+0.0%	$11.0M
CLDXCelldex Therapeutics Inc New	2.8%	4.3%	200,000	-39.4%	$7.4M
BCRXBiocryst Pharmaceuticals Inc	2.7%	3.6%	721,504	-21.8%	$7.2M
PROFProfound Med Corp	2.1%	2.2%	828,118	+0.0%	$5.5M
TLPHTalphera Inc	2.0%	1.0%	5,169,501	+54.1%	$5.3M
AVIRAtea Pharmaceuticals Inc	1.9%	2.6%	1,070,550	-8.6%	$5.0M
MYOMyomo Inc	1.4%	1.1%	3,637,886	-5.4%	$3.8M
OVIDOvid Therapeutics Inc	1.1%	1.0%	1,107,994	+0.0%	$3.0M
NRXSNeuraxis Inc	1.1%	0.7%	508,055	+77.6%	$3.0M
ABVXAbivax SA	1.0%	New	20,869	—	$2.8M
NSPRInspiremd Inc	1.0%	2.6%	3,905,743	+0.0%	$2.7M
RGNTRegentis Biomaterials Ltd	0.9%	0.3%	701,685	+179.0%	$2.5M
PYPDPolypid Ltd	0.7%	1.1%	389,455	-34.9%	$2.0M
BFRIBiofrontera Inc	0.5%	0.4%	1,275,609	+9.6%	$1.2M
KURAKura Oncology Inc	0.4%	0.3%	100,000	+0.0%	$1.1M
85209E208Spruce Biosciences Inc	0.4%	New	20,000	—	$1.1M
AQSTAquestive Therapeutics Inc	0.4%	0.4%	250,000	+0.0%	$1.0M
OKUROnkure Therapeutics Inc	0.3%	0.8%	150,000	-66.2%	$684K
PEPGPepgen Inc	0.2%	New	350,000	—	$630K

What Rosalind Advisors, Inc. bought and sold in Q2 2026, against Q1 2026.

New positions

ABVX Abivax SA1.0% of 13F
Spruce Biosciences Inc0.4% of 13F
PEPG Pepgen Inc0.2% of 13F

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year: +0.5% /yr; S&P 500 +11.7%
3 years: +18.5% /yr; S&P 500 +16.5%
5 years: —

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$266.2M	29
Q1 2026	$244.1M	32
Q4 2025	$274.5M	29
Q3 2025	$283.0M	29
Q2 2025	$206.6M	29
Q1 2025	$205.2M	31
Q4 2024	$185.7M	28
Q3 2024	$150.7M	29
Q2 2024	$126.5M	35
Q1 2024	$106.9M	31
Q4 2023	$119.5M	27

Questions about Rosalind Advisors, Inc.'s portfolio

What stocks does Rosalind Advisors, Inc. own?

Rosalind Advisors, Inc.'s latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 29 positions worth $266.2M. The largest are Delcath Sys Inc (DCTH) at 15.6%, Fennec Pharmaceuticals Inc (FENC) at 12.9%, Xeris Biopharma Holdings Inc (XERS) at 8.7%, Savara Inc (SVRA) at 7.4% and Verastem Inc (VSTM) at 5.7%.

What did Rosalind Advisors, Inc. buy last quarter?

In Q2 2026, Rosalind Advisors, Inc. added a new position in Abivax SA (ABVX), a new position in Spruce Biosciences Inc, a new position in Pepgen Inc (PEPG), Regentis Biomaterials Ltd (RGNT) (+179.0% shares), Verastem Inc (VSTM) (+86.4% shares) and Neuraxis Inc (NRXS) (+77.6% shares), compared with its Q1 2026 filing.

What did Rosalind Advisors, Inc. sell last quarter?

In Q2 2026, Rosalind Advisors, Inc. sold all of Cg Oncology Inc (CGON), sold all of Viridian Therapeutics Inc (VRDN), sold all of Definium Therapeutics Inc, sold all of Lipocine Inc New (LPCN), sold all of Avalo Therapeutics Inc (AVTX), Onkure Therapeutics Inc (OKUR) (-66.2% shares), Celldex Therapeutics Inc New (CLDX) (-39.4% shares) and Polypid Ltd (PYPD) (-34.9% shares), compared with its Q1 2026 filing.

How has Rosalind Advisors, Inc.'s portfolio performed?

A portfolio copying Rosalind Advisors, Inc.'s 20 largest 13F holdings each quarter, from the day each filing was public, returned +18.5% a year over the last 3 years, against +16.5% for the S&P 500. Over 1 year: +0.5% against +11.7%.

When is Rosalind Advisors, Inc.'s next 13F filing due?

13F filings are due 45 days after each quarter ends. Rosalind Advisors, Inc.'s filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.